A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor

Uncommon mutations account for 10–15% of epidermal growth factor receptor (EGFR) mutations in patients with non‐small‐cell lung cancer. Afatinib is currently the most efficient EGFR‐tyrosine kinase inhibitor (TKI) against uncommon EGFR mutations. Here we report a 56‐year‐old woman presenting with pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lun‐Che, Shih, Jin‐Yuan, Yu, Chong‐Jen, Yang, Ching‐Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456914/
https://www.ncbi.nlm.nih.gov/pubmed/31007929
http://dx.doi.org/10.1002/rcr2.425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456914/
https://www.ncbi.nlm.nih.gov/pubmed/31007929
http://dx.doi.org/10.1002/rcr2.425

Ejemplares similares